These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Diener HC. Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293 [Abstract] [Full Text] [Related]
23. Oral almotriptan: practical uses in the acute treatment of migraine. Dowson AJ. Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532 [Abstract] [Full Text] [Related]
24. Acute treatment of paediatric migraine: a meta-analysis of efficacy. Silver S, Gano D, Gerretsen P. J Paediatr Child Health; 2008 Jan; 44(1-2):3-9. PubMed ID: 17854415 [Abstract] [Full Text] [Related]
25. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Dahlöf CG, Pascual J, Dodick DW, Dowson AJ. Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240 [Abstract] [Full Text] [Related]
26. [28. Acute therapy and prevention of migraine]. Diener HC. MMW Fortschr Med; 2002 Jan 24; 144(3-4):I-X; quiz XI-II. PubMed ID: 11862804 [No Abstract] [Full Text] [Related]
27. [After 2 hours the drug should have an effect]. MMW Fortschr Med; 2006 Aug 03; 148(31-32):8. PubMed ID: 16937865 [No Abstract] [Full Text] [Related]
28. Almotriptan for the treatment of acute migraine: a review of early intervention trials. Antonaci F, De Cillis I, Cuzzoni MG, Allena M. Expert Rev Neurother; 2010 Mar 03; 10(3):351-64. PubMed ID: 20187858 [Abstract] [Full Text] [Related]
29. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J. Cephalalgia; 2008 Apr 03; 28(4):383-91. PubMed ID: 18294251 [Abstract] [Full Text] [Related]
31. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Burstein R, Collins B, Jakubowski M. Ann Neurol; 2004 Jan 03; 55(1):19-26. PubMed ID: 14705108 [Abstract] [Full Text] [Related]
32. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. Pascual J, García-Moncó C, Roig C, Yusta Izquierdo A, López-Gil A, eMAX Study Group. Headache; 2005 Oct 03; 45(9):1140-50. PubMed ID: 16178944 [Abstract] [Full Text] [Related]
36. [Bonus-malus regulations in the framework of the AVWG guideline-suitable migraine therapy are possible]. MMW Fortschr Med; 2007 May 21; 149 Suppl 2():102-3. PubMed ID: 17724980 [No Abstract] [Full Text] [Related]
37. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. Elkind AH, MacGregor EA. Expert Rev Neurother; 2008 May 21; 8(5):723-36. PubMed ID: 18457529 [Abstract] [Full Text] [Related]
38. Use of almotriptan in triptan-experienced and triptan-naïve patients. Pascual J, Diener HC. Curr Med Res Opin; 2007 Oct 21; 23(10):2433-40. PubMed ID: 17723158 [Abstract] [Full Text] [Related]
39. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC. Headache; 2009 Oct 21; 49(9):1283-97. PubMed ID: 19751371 [Abstract] [Full Text] [Related]